1. Aged >=18 years at time of signing Informed Consent Form, 2. Patients with confirmed cases meeting the following criteria (1) Epidemiology history, (2) Clinical manifestations (epidemiological history and in accordance with any of the following 2 items, no clear epidemiology history, conforms to 3 items in clinical manifestations): Fever and / or respiratory symptoms, In the early stage of the disease, the total leukocyte count was normal or decreased, or the lymphocyte count decreased, Early chest imaging showed multiple small plaques and interstitial changes, which were evident in the extraneous lung. Further, multiple ground-glass shadows and infiltration shadows were found in both lungs, and lung consolidation and pleural effusion were rare in severe cases, (3) Having one of the following etiological evidence: Respiratory tract, blood or fecal samples RT-PCR confirmed infection with 2019-nCoV, The virus genes of the above samples were sequenced and highly homologous to the 2019-nCoV, 3. Patients who meet the following mild and normal criteria, Mild: mild clinical symptoms, no signs of pneumonia on imaging, Normal: fever, respiratory symptoms, imaging manifestations of pneumonia, 4. Antimalarial drugs such as chloroquine and hydroxychloroquine were not used within 3 months, 5. Agree not to participate in other clinical researchers within 30 days from the first administration of the study drug to the last administration, 6. Eligible fertile subjects (male and female) must agree to use effective birth control (hormone or barrier or abstinence) with their partner during the trial period and for at least 3 months after the last dose, 7. Patients who agree to participate in this study and are willing to sign the informed consent form voluntarily.

1. Aged >=18 years at time of signing Informed Consent Form, 2. Patients with confirmed cases meeting the following criteria (1) Epidemiology history, (2) Clinical manifestations (epidemiological history and in accordance with any of the following 2 items, no clear epidemiology history, conforms to 3 items in clinical manifestations): Fever and / or respiratory symptoms, In the early stage of the disease, the total leukocyte count was normal or decreased, or the lymphocyte count decreased, Early chest imaging showed multiple small plaques and interstitial changes, which were evident in the extraneous lung. Further, multiple ground-glass shadows and infiltration shadows were found in both lungs, and lung consolidation and pleural effusion were rare in severe cases, (3) Having one of the following etiological evidence: Respiratory tract, blood or fecal samples RT-PCR confirmed infection with 2019-nCoV, The virus genes of the above samples were sequenced and highly homologous to the 2019-nCoV, 3. Patients who meet the following mild and normal criteria, Mild: mild clinical symptoms, no signs of pneumonia on imaging, Normal: fever, respiratory symptoms, imaging manifestations of pneumonia, 4. Antimalarial drugs such as chloroquine and hydroxychloroquine were not used within 3 months, 5. Agree not to participate in other clinical researchers within 30 days from the first administration of the study drug to the last administration, 6. Eligible fertile subjects (male and female) must agree to use effective birth control (hormone or barrier or abstinence) with their partner during the trial period and for at least 3 months after the last dose, 7. Patients who agree to participate in this study and are willing to sign the informed consent form voluntarily.